# Human ISG15 deficiency unveils impaired healing of ulcerations via type I interferon–mediated fibrosis

**Authors:** Christos Sazeides, Lorenzo Cuollo, Ikjot Sidhu, Haley E. Randolph, Marta Martin-Fernandez, Sofija Buta, O’ Jay Stewart, Rachel Geltman, Jonas A. Adalsteinsson, Robert G. Phelps, Amir Horowitz, David Stein, Mariam Youssef, Andres Martinez-Muniz, Michelle Hernandez, Michail S. Lionakis, Alexis Boneparth, Joshua D. Milner, Shruti Naik, Dusan Bogunovic

PMC · DOI: 10.70962/jhi.20250011 · Journal of Human Immunity · 2026-02-24

## TL;DR

People with ISG15 deficiency have trouble healing wounds due to chronic inflammation and fibrosis caused by high levels of interferon.

## Contribution

This study identifies how ISG15 deficiency leads to fibrosis and impaired wound healing through IFN-I-dependent mechanisms.

## Key findings

- ISG15 deficiency causes increased IFN-I–dependent apoptosis and fibrosis in skin and lung tissues.
- ISG15 knockout cells show enhanced epithelial-to-mesenchymal transition and impaired wound healing.
- Macrophage polarization and myofibroblast activation are altered in ISG15-deficient patients.

## Abstract

Human ISG15 deficiency is a monogenic syndrome that poises individuals to a proapoptotic and profibrotic state that can lead to lung and skin damage with scarring and impaired function via chronic inflammation.

ISG15 deficiency is a type I interferonopathy characterized by elevated circulating type I interferon (IFN-I), intracranial calcifications, fibrotic skin lesions, and occasionally inflammatory lung disease. However, the mechanisms driving immune-mediated fibrosis remain poorly understood. In this study, we combined molecular biology approaches with spatial transcriptomics in ex vivo patient samples and in vitro models to characterize a novel loss-of-function ISG15 variant and to elucidate disease-associated molecular pathways. Analysis of patient skin biopsies revealed increased IFN-I–dependent apoptosis, altered macrophage polarization, enhanced epithelial-to-mesenchymal transition (EMT), and myofibroblast activation. In vitro, ISG15 knockout (KO), but not wild-type (WT), epithelial cells were predisposed to EMT following combined TGF-β and IFN-I stimulation. Additionally, ISG15 KO fibroblasts displayed impaired mechanical wound healing and increased IFN-I–induced apoptosis compared with WT cells. Collectively, our findings suggest that chronic IFN-I exposure in ISG15 deficiency disrupts wound repair, skews macrophage activation, and promotes EMT, contributing to fibrosis across multiple organ systems.

## Linked entities

- **Genes:** ISG15 (ISG15 ubiquitin like modifier) [NCBI Gene 9636]

## Full-text entities

- **Genes:** IFNB1 (interferon beta 1) [NCBI Gene 3456] {aka IFB, IFF, IFN-beta, IFNB}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, MGI [NCBI Gene 8144], ZBP1 (Z-DNA binding protein 1) [NCBI Gene 81030] {aka C20orf183, DAI, DLM-1, DLM1}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, Cd163 (CD163 antigen) [NCBI Gene 93671] {aka CD163v2, CD163v3}, IFNAR2 (interferon alpha and beta receptor subunit 2) [NCBI Gene 3455] {aka IFN-R, IFN-R-2, IFN-alpha-REC, IFNABR, IFNARB, IMD45}, CXCL12 (C-X-C motif chemokine ligand 12) [NCBI Gene 6387] {aka IRH, PBSF, SCYB12, SDF1, TLSF, TPAR1}, UBA7 (ubiquitin like modifier activating enzyme 7) [NCBI Gene 7318] {aka D8, UBA1B, UBE1L, UBE2, UBE7}, COL16A1 (collagen type XVI alpha 1 chain) [NCBI Gene 1307] {aka 447AA, FP1572}, CXCL2 (C-X-C motif chemokine ligand 2) [NCBI Gene 2920] {aka CINC-2a, GRO2, GROb, MGSA-b, MIP-2a, MIP2}, ITGAL (integrin subunit alpha L) [NCBI Gene 3683] {aka CD11A, EV6, HNA-5, LFA-1, LFA1A}, SAMHD1 (SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1) [NCBI Gene 25939] {aka CHBL2, DCIP, HDDC1, MOP-5, SBBI88, hSAMHD1}, MX1 (MX dynamin like GTPase 1) [NCBI Gene 4599] {aka IFI-78K, IFI78, MX, MxA, lncMX1-215}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, IFNA2 (interferon alpha 2) [NCBI Gene 3440] {aka IFN-alpha-2, IFN-alphaA, IFNA, IFNA2B, leIF A}, Fcgr3 (Fc receptor, IgG, low affinity III) [NCBI Gene 14131] {aka CD16}, JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}, PCSK1 (proprotein convertase subtilisin/kexin type 1) [NCBI Gene 5122] {aka BMIQ12, NEC1, PC1, PC1/3, PC3, SPC3}, IFI27 (interferon alpha inducible protein 27) [NCBI Gene 3429] {aka FAM14D, ISG12, ISG12A, P27}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, JAK1 (Janus kinase 1) [NCBI Gene 3716] {aka AIIDE, JAK1A, JAK1B, JTK3}, MRC1 (mannose receptor C-type 1) [NCBI Gene 4360] {aka CD206, CLEC13D, CLEC13DL, MMR, MRC1L1, bA541I19.1}, COL3A1 (collagen type III alpha 1 chain) [NCBI Gene 1281] {aka EDS4A, EDSVASC, PMGEDSV}, COPA (coat protein complex I subunit alpha) [NCBI Gene 1314] {aka AIAISD, AIAISD1, AILJK, HEP-COP, alpha-COP}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}, ITGB1 (integrin subunit beta 1) [NCBI Gene 3688] {aka CD29, FNRB, GPIIA, MDF2, MSK12, VLA-BETA}, IFIT1 (interferon induced protein with tetratricopeptide repeats 1) [NCBI Gene 3434] {aka C56, G10P1, IFI-56, IFI-56K, IFI56, IFIT-1}, FCGR3A (Fc gamma receptor IIIa) [NCBI Gene 2214] {aka CD16-II, CD16A, FCG3, FCGR3, FCRIIIA, FcGRIIIA}, IFI44L (interferon induced protein 44 like) [NCBI Gene 10964] {aka C1orf29, GS3686, TLDC5B}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, SIGLEC1 (sialic acid binding Ig like lectin 1) [NCBI Gene 6614] {aka CD169, SIGLEC-1, SN}, RIPK1 (receptor interacting serine/threonine kinase 1) [NCBI Gene 8737] {aka AIEFL, IMD57, RIP, RIP-1, RIP1}, CASP8 (caspase 8) [NCBI Gene 841] {aka ALPS2B, CAP4, Casp-8, FLICE, MACH, MCH5}, STAT2 (signal transducer and activator of transcription 2) [NCBI Gene 6773] {aka IMD44, ISGF-3, P113, PTORCH3, STAT113}, MAP1LC3B (microtubule associated protein 1 light chain 3 beta) [NCBI Gene 81631] {aka ATG8F, LC3B, MAP1A/1BLC3, MAP1LC3B-a}, ABL2 (ABL proto-oncogene 2, non-receptor tyrosine kinase) [NCBI Gene 27] {aka ABLL, ARG}, OAS1 (2'-5'-oligoadenylate synthetase 1) [NCBI Gene 4938] {aka E18/E16, IFI-4, IMD100, OIAS, OIASI}, USP18 (ubiquitin specific peptidase 18) [NCBI Gene 11274] {aka ISG43, PTORCH2, UBP43}, TREX1 (three prime repair exonuclease 1) [NCBI Gene 11277] {aka AGS1, CRV, DRN3, HERNS, RVCLS}, HERC5 (HECT and RLD domain containing E3 ubiquitin protein ligase 5) [NCBI Gene 51191] {aka CEB1, CEBP1}, COL5A1 (collagen type V alpha 1 chain) [NCBI Gene 1289] {aka EDSC, EDSCL1, FMDMF}, ADAR (adenosine deaminase RNA specific) [NCBI Gene 103] {aka ADAR1, AGS6, DRADA, DSH, DSRAD, G1P1}, POSTN (periostin) [NCBI Gene 10631] {aka OSF-2, OSF2, PDLPOSTN, PN}, RIPK3 (receptor interacting serine/threonine kinase 3) [NCBI Gene 11035] {aka RIP3}, TYK2 (tyrosine kinase 2) [NCBI Gene 7297] {aka IMD35, JTK1}, STING1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 340061] {aka ERIS, MITA, MPYS, NET23, SAVI, STING}, UBE2L6 (ubiquitin conjugating enzyme E2 L6) [NCBI Gene 9246] {aka RIG-B, UBCH8}, MLKL (mixed lineage kinase domain like pseudokinase) [NCBI Gene 197259] {aka hMLKL}, Rb1 (RB transcriptional corepressor 1) [NCBI Gene 19645] {aka Rb, Rb-1, p110-RB1, pRb, pp105}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}, CD34 (CD34 molecule) [NCBI Gene 947], STAT1 (signal transducer and activator of transcription 1) [NCBI Gene 6772] {aka CANDF7, IMD31A, IMD31B, IMD31C, ISGF-3, STAT91}, IRF9 (interferon regulatory factor 9) [NCBI Gene 10379] {aka IRF-9, ISGF3, ISGF3G, p48}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, ARG1 (arginase 1) [NCBI Gene 383], IL12B (interleukin 12B) [NCBI Gene 3593] {aka CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF}, ROBO3 (roundabout guidance receptor 3) [NCBI Gene 64221] {aka HGPPS, HGPPS1, HGPS, RBIG1, RIG1}, ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}
- **Diseases:** basal (MESH:D002280), necrosis (MESH:D009336), parakeratosis (MESH:D010241), sleep-related breathing disorder (MESH:D012891), fungal (MESH:D009181), UMAP (MESH:C567162), ST (MESH:D008569), pulmonary hypertension (MESH:D006976), pulmonary fibrosis (MESH:D011658), interstitial lung disease (MESH:D017563), infection (MESH:D007239), right ventricular dysfunction (MESH:D018497), cytotoxicity (MESH:D064420), end-stage lung disease (MESH:D058625), panniculitis (MESH:D015434), AGS (MESH:C535607), Psoriasis (MESH:D011565), hypoxemia (MESH:D000860), sclerosis (MESH:D012598), Type I interferonopathies (MESH:D006969), inflammatory lung pathologies (MESH:D016726), calcifications (MESH:D002114), inflammatory lung disease (MESH:D008171), ISG15 deficiency (OMIM:616126), shortness of breath (MESH:D004417), lung tissue damage (MESH:D055370), mycobacterial disease (MESH:C564468), Fibrosis (MESH:D005355), chronic inflammation (MESH:D007249), vasculitis (MESH:D014657), chronic wounds (MESH:D014947), monogenic diseases (MESH:D004194), fibrotic skin lesions (MESH:D012871), chilblains (MESH:D002647), intracranial calcifications (MESH:C537905), inguinal cutaneous lesion (MESH:D006552)
- **Chemicals:** Tween-20 (MESH:D011136), PBS (MESH:D007854), eosin (MESH:D004801), chloroquine (MESH:D002738), Formalin (MESH:D005557), steroids (MESH:D013256), Lipofectamine 2000 (MESH:C086724), H&amp;E (MESH:D006371), necrostatin-1 (MESH:C507699), PI (MESH:D011419), Clonase II (-), hematoxylin (MESH:D006416), DTT (MESH:D004229), ruxolitinib (MESH:C540383), TBS (MESH:D013725), FITC (MESH:D016650), paraffin (MESH:D010232), oxygen (MESH:D010100)
- **Species:** Aspergillus (genus) [taxon 5052], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** c.463insC, p.Val104Met, c.352C>T, p.Arg155Pro, p.Gln118*
- **Cell lines:** fibroblasts — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0594), hTERT — Homo sapiens (Human), Transformed cell line (CVCL_E232), HEK293T — Homo sapiens (Human), Transformed cell line (CVCL_0063), A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12931375/full.md

## Figures

13 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12931375/full.md

## References

83 references — full list in the complete paper: https://tomesphere.com/paper/PMC12931375/full.md

---
Source: https://tomesphere.com/paper/PMC12931375